Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and spray… Read more
Market Cap & Net Worth: Caplin Point Laboratories Limited (CAPLIPOINT)
Caplin Point Laboratories Limited (NSE:CAPLIPOINT) has a market capitalization of $1.44 Billion (₹124.29 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #11876 globally and #508 in its home market, demonstrating a -1.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Caplin Point Laboratories Limited's stock price ₹1635.10 by its total outstanding shares 76011696 (76.01 Million).
Caplin Point Laboratories Limited Market Cap History: 2015 to 2026
Caplin Point Laboratories Limited's market capitalization history from 2015 to 2026. Data shows growth from $237.40 Million to $1.44 Billion (19.52% CAGR).
Index Memberships
Caplin Point Laboratories Limited is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$1.27 Trillion | 0.03% | #400 of 500 |
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$68.11 Billion | 0.53% | #68 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.32 Trillion | 0.03% | #432 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$188.65 Billion | 0.19% | #181 of 250 |
Weight: Caplin Point Laboratories Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Caplin Point Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Caplin Point Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Caplin Point Laboratories Limited's market cap is 0.08 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.30x
Caplin Point Laboratories Limited's market cap is 0.30 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $290.40 Million | $3.09 Billion | $584.14 Million | 0.09x | 0.50x |
| 2017 | $535.63 Million | $4.02 Billion | $956.12 Million | 0.13x | 0.56x |
| 2018 | $325.32 Million | $5.40 Billion | $1.45 Billion | 0.06x | 0.22x |
| 2019 | $257.54 Million | $6.49 Billion | $1.77 Billion | 0.04x | 0.15x |
| 2020 | $436.67 Million | $8.64 Billion | $2.15 Billion | 0.05x | 0.20x |
| 2021 | $743.08 Million | $10.62 Billion | $2.42 Billion | 0.07x | 0.31x |
| 2022 | $620.94 Million | $12.71 Billion | $3.00 Billion | 0.05x | 0.21x |
| 2023 | $1.19 Billion | $14.68 Billion | $3.76 Billion | 0.08x | 0.32x |
| 2024 | $2.19 Billion | $16.96 Billion | $4.57 Billion | 0.13x | 0.48x |
| 2025 | $1.61 Billion | $19.40 Billion | $5.36 Billion | 0.08x | 0.30x |
Competitor Companies of CAPLIPOINT by Market Capitalization
Companies near Caplin Point Laboratories Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Caplin Point Laboratories Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Caplin Point Laboratories Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Caplin Point Laboratories Limited's market cap moved from $237.40 Million to $ 1.44 Billion, with a yearly change of 19.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹1.44 Billion | -11.04% |
| 2025 | ₹1.61 Billion | -26.50% |
| 2024 | ₹2.19 Billion | +84.99% |
| 2023 | ₹1.19 Billion | +91.07% |
| 2022 | ₹620.94 Million | -16.44% |
| 2021 | ₹743.08 Million | +70.17% |
| 2020 | ₹436.67 Million | +69.55% |
| 2019 | ₹257.54 Million | -20.83% |
| 2018 | ₹325.32 Million | -39.26% |
| 2017 | ₹535.63 Million | +84.45% |
| 2016 | ₹290.40 Million | +22.32% |
| 2015 | ₹237.40 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Caplin Point Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.44 Billion USD |
| MoneyControl | $1.44 Billion USD |
| MarketWatch | $1.44 Billion USD |
| marketcap.company | $1.44 Billion USD |
| Reuters | $1.44 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.